Lupin gets 5 USFDA observations for Vizag facility

The inspection for the API facility at Vizag closed with five 483 observations, Lupin said.

New Delhi: Drug firm Lupin on Saturday said it has received five observations from the US health regulator after inspection of its Vizag facility in Andhra Pradesh.

The inspection of company's Vizag API manufacturing facility by the United States Food and Drug Administration (USFDA) has been completed, Lupin said in a filing to BSE.

The inspection was carried out between January 13, 2020, and January 17, 2020, it added.

The inspection for the API facility at Vizag closed with five 483 observations, Lupin said.

Read also: Lupin appoints J Alan Butcher as Chief Corporate Development Officer

"We are fully committed to adherence to CGMP regulations and uphold high-quality standards across all our manufacturing sites. We are confident of addressing the observations to the US FDA's satisfaction," Lupin MD Nilesh Gupta said.

Read also: Lupin gets 2 observations from USFDA for Nagpur facility